{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T13:46:40Z","timestamp":1791812800730,"version":"4.3.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC112-2314-B-075 A-003-MY3-2"],"award-info":[{"award-number":["NSTC112-2314-B-075 A-003-MY3-2"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"publisher","award":["TCVGH-1127307D"],"award-info":[{"award-number":["TCVGH-1127307D"]}],"id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"DOI":"10.1186\/s12890-026-04501-x","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T11:14:39Z","timestamp":1784200479000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Progressive pulmonary fibrosis criteria predict mortality in treated idiopathic pulmonary fibrosis: a prospective cohort study"],"prefix":"10.1186","volume":"26","author":[{"given":"Yu-Cheng","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Luen","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiann-Yi","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hsuan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pin-Kuei","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"4501_CR1","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1001\/jama.2024.3669","volume":"331","author":"TM Maher","year":"2024","unstructured":"Maher TM. Interstitial lung disease: a review. JAMA. 2024;331:1655\u201365. https:\/\/doi.org\/10.1001\/jama.2024.3669.","journal-title":"JAMA"},{"key":"4501_CR2","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMra1705751","volume":"378","author":"DJ Lederer","year":"2018","unstructured":"Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. N Engl J Med. 2018;378:1811\u201323. https:\/\/doi.org\/10.1056\/NEJMra1705751.","journal-title":"N Engl J Med"},{"key":"4501_CR3","doi-asserted-by":"publisher","unstructured":"Jeganathan N, Sathananthan M. The prevalence and burden of interstitial lung diseases in the USA. ERJ Open Res. 2022;8. https:\/\/doi.org\/10.1183\/23120541.00630-2021.","DOI":"10.1183\/23120541.00630-2021"},{"key":"4501_CR4","doi-asserted-by":"publisher","first-page":"2101396","DOI":"10.1183\/13993003.01396-2021","volume":"59","author":"JM Oldham","year":"2022","unstructured":"Oldham JM, Lee CT, Wu Z, Bowman WS, Pugashetti JV, Dao N, et al. Lung function trajectory in progressive fibrosing interstitial lung disease. Eur Respir J. 2022;59:2101396. https:\/\/doi.org\/10.1183\/13993003.01396-2021.","journal-title":"Eur Respir J"},{"key":"4501_CR5","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1183\/09031936.00185114","volume":"46","author":"J Hutchinson","year":"2015","unstructured":"Hutchinson J, Fogarty A, Hubbard R, McKeever T. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J. 2015;46:795\u2013806. https:\/\/doi.org\/10.1183\/09031936.00185114.","journal-title":"Eur Respir J"},{"key":"4501_CR6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12931-021-01791-z","volume":"22","author":"TM Maher","year":"2021","unstructured":"Maher TM, Bendstrup E, Dron L, Langley J, Smith G, Khalid JM, et al. Global incidence and prevalence of idiopathic pulmonary fibrosis. Respir Res. 2021;22:197. https:\/\/doi.org\/10.1186\/s12931-021-01791-z.","journal-title":"Respir Res"},{"key":"4501_CR7","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1007\/s40265-023-01950-0","volume":"83","author":"F Bonella","year":"2023","unstructured":"Bonella F, Spagnolo P, Ryerson C. Current and future treatment landscape for idiopathic pulmonary fibrosis. Drugs. 2023;83:1581\u201393. https:\/\/doi.org\/10.1007\/s40265-023-01950-0.","journal-title":"Drugs"},{"key":"4501_CR8","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380:2518\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1903076.","journal-title":"N Engl J Med"},{"key":"4501_CR9","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","volume":"8","author":"AU Wells","year":"2020","unstructured":"Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med. 2020;8:453\u201360. https:\/\/doi.org\/10.1016\/S2213-2600(20)30036-9.","journal-title":"Lancet Respir Med"},{"key":"4501_CR10","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1016\/j.chest.2021.06.049","volume":"160","author":"T Petnak","year":"2021","unstructured":"Petnak T, Lertjitbanjong P, Thongprayoon C, Moua T. Impact of Antifibrotic Therapy on mortality and acute exacerbation in idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Chest. 2021;160:1751\u201363. https:\/\/doi.org\/10.1016\/j.chest.2021.06.049.","journal-title":"Chest"},{"key":"4501_CR11","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1186\/s12890-021-01783-1","volume":"21","author":"JP Finnerty","year":"2021","unstructured":"Finnerty JP, Ponnuswamy A, Dutta P, Abdelaziz A, Kamil H. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis. BMC pulm med. 2021;21:411. https:\/\/doi.org\/10.1186\/s12890-021-01783-1.","journal-title":"BMC pulm med"},{"key":"4501_CR12","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s00228-024-03720-7","volume":"80","author":"M Kou","year":"2024","unstructured":"Kou M, Jiao Y, Li Z, Wei B, Li Y, Cai Y, et al. Real-world safety and effectiveness of pirfenidone and nintedanib in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2024;80:1445\u201360. https:\/\/doi.org\/10.1007\/s00228-024-03720-7.","journal-title":"Eur J Clin Pharmacol"},{"key":"4501_CR13","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s12890-018-0736-z","volume":"18","author":"GA Margaritopoulos","year":"2018","unstructured":"Margaritopoulos GA, Trachalaki A, Wells AU, Vasarmidi E, Bibaki E, Papastratigakis G, et al. Pirfenidone improves survival in IPF: results from a real-life study. BMC pulm med. 2018;18:177. https:\/\/doi.org\/10.1186\/s12890-018-0736-z.","journal-title":"BMC pulm med"},{"key":"4501_CR14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.rmed.2019.04.016","volume":"153","author":"SD Nathan","year":"2019","unstructured":"Nathan SD, Costabel U, Albera C, Behr J, Wuyts WA, Kirchgaessler K-U, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment. Respir Med. 2019;153:44\u201351. https:\/\/doi.org\/10.1016\/j.rmed.2019.04.016.","journal-title":"Respir Med"},{"key":"4501_CR15","doi-asserted-by":"publisher","first-page":"e0261684","DOI":"10.1371\/journal.pone.0261684","volume":"16","author":"EG Lee","year":"2021","unstructured":"Lee EG, Lee T-H, Hong Y, Ryoo J, Heo JW, Gil BM, et al. Effects of low-dose pirfenidone on survival and lung function decline in patients with idiopathic pulmonary fibrosis (IPF): Results from a real-world study. PLoS ONE. 2021;16:e0261684. https:\/\/doi.org\/10.1371\/journal.pone.0261684.","journal-title":"PLoS ONE"},{"key":"4501_CR16","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.chest.2023.11.035","volume":"165","author":"JS Kim","year":"2024","unstructured":"Kim JS, Murray S, Yow E, Anstrom KJ, Kim HJ, Flaherty KR, et al. Comparison of pirfenidone and nintedanib: post hoc analysis of the CleanUP-IPF study. Chest. 2024;165:1163\u201373. https:\/\/doi.org\/10.1016\/j.chest.2023.11.035.","journal-title":"Chest"},{"key":"4501_CR17","doi-asserted-by":"publisher","first-page":"107515","DOI":"10.1016\/j.rmed.2023.107515","volume":"222","author":"T Pitre","year":"2024","unstructured":"Pitre T, Lupas D, Ebeido I, Colak A, Modi M, Kachkovski GV, et al. Prognostic factors associated with mortality in acute exacerbations of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. Respir Med. 2024;222:107515. https:\/\/doi.org\/10.1016\/j.rmed.2023.107515.","journal-title":"Respir Med"},{"key":"4501_CR18","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.4187\/respcare.11754","volume":"69","author":"YY Cheng","year":"2024","unstructured":"Cheng YY, Lee YC, Liao YW, Liu MC, Wu YC, Hsu CY, et al. A summed score from cardiopulmonary exercise test parameters predicts 1-year mortality in newly diagnosed interstitial lung disease. Respir Care. 2024;69:1305\u201313. https:\/\/doi.org\/10.4187\/respcare.11754.","journal-title":"Respir Care"},{"key":"4501_CR19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s40001-024-01673-2","volume":"29","author":"YW Liao","year":"2024","unstructured":"Liao YW, Liu MC, Wu YC, Hsu CY, Huang WN, Chen YH, et al. Factors influencing long-term outcomes in fibrotic interstitial lung disease (F-ILD) diagnosed through multidisciplinary discussion (MDD): a prospective cohort study. Eur J Med Res. 2024;29:91. https:\/\/doi.org\/10.1186\/s40001-024-01673-2.","journal-title":"Eur J Med Res"},{"key":"4501_CR20","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic pulmonary fibrosis (an Update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205:e18\u201347. https:\/\/doi.org\/10.1164\/rccm.202202-0399ST.","journal-title":"Am J Respir Crit Care Med"},{"key":"4501_CR21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40001-024-01644-7","volume":"29","author":"YW Liao","year":"2024","unstructured":"Liao YW, Chen YM, Liu MC, Wu YC, Hsu CY, Fu PK, et al. Multidisciplinary-derived clinical score for accurate prediction of long-term mortality in fibrotic lung disease patients. Eur J Med Res. 2024;29:69. https:\/\/doi.org\/10.1186\/s40001-024-01644-7.","journal-title":"Eur J Med Res"},{"key":"4501_CR22","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jjcc.2024.03.012","volume":"84","author":"YW Chen","year":"2024","unstructured":"Chen YW, Lai CH, Liao YW, Liu MC, Wu YC, Hsu CY, et al. A composite score based on cardiovascular parameters can predict the mortality risk of patients with newly diagnosed interstitial lung disease: A prospective observational study. J Cardiol. 2024;84:287\u201393. https:\/\/doi.org\/10.1016\/j.jjcc.2024.03.012.","journal-title":"J Cardiol"},{"key":"4501_CR23","doi-asserted-by":"publisher","unstructured":"Tseng CW, Wang KL, Fu PK, Huang CY, Hsieh TY, Hsieh CW, et al. GAP score and CA-153 associated with one-year mortality in anti-MDA-5 antibody-positive patients: a real-world experience. J Clin Med. 2021;10. https:\/\/doi.org\/10.3390\/jcm10225241.","DOI":"10.3390\/jcm10225241"},{"key":"4501_CR24","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12890-025-03521-3","volume":"25","author":"MY Tsai","year":"2025","unstructured":"Tsai MY, Huang KT, Hsu CY, Yu YH, Fu PK. Reference values for the 1-minute sit-to-stand test to assess functional capacity and short-term mortality in people with idiopathic pulmonary fibrosis and fibrotic connective tissue related interstitial lung diseases: a prospective real-world cohort study. BMC Pulm Med. 2025;25:61. https:\/\/doi.org\/10.1186\/s12890-025-03521-3.","journal-title":"BMC Pulm Med"},{"key":"4501_CR25","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1378\/chest.93.3.580","volume":"93","author":"DA Mahler","year":"1988","unstructured":"Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest. 1988;93:580\u20136. https:\/\/doi.org\/10.1378\/chest.93.3.580.","journal-title":"Chest"},{"key":"4501_CR26","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1183\/09031936.00102509","volume":"34","author":"PW Jones","year":"2009","unstructured":"Jones PW, Harding G, Berry P, Wiklund I, Chen W-H, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34:648\u201354. https:\/\/doi.org\/10.1183\/09031936.00102509.","journal-title":"Eur Respir J"},{"key":"4501_CR27","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware","year":"1992","unstructured":"Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473\u201383.","journal-title":"Med Care"},{"key":"4501_CR28","doi-asserted-by":"publisher","unstructured":"Jones PW, Quirk FH, Baveystock CM. The St George\u2019s Respiratory Questionnaire. Respir Med. 1991;25\u201331. https:\/\/doi.org\/10.1016\/s0954-6111(06)80166-6. Discussion 33\u201337.","DOI":"10.1016\/s0954-6111(06)80166-6"},{"key":"4501_CR29","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1164\/rccm.201908-1590ST","volume":"200","author":"BL Graham","year":"2019","unstructured":"Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, et al. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med. 2019;200:e70\u201388. https:\/\/doi.org\/10.1164\/rccm.201908-1590ST.","journal-title":"Am J Respir Crit Care Med"},{"key":"4501_CR30","doi-asserted-by":"publisher","unstructured":"Graham BL, Brusasco V, Burgos F, Cooper BG, Jensen R, Kendrick A, et al. Executive Summary: 2017 ERS\/ATS standards for single-breath carbon monoxide uptake in the lung. Eur Respir J. 2017;49. https:\/\/doi.org\/10.1183\/13993003.E0016-2016.","DOI":"10.1183\/13993003.E0016-2016"},{"key":"4501_CR31","first-page":"188","volume":"12","author":"WP Glasheen","year":"2019","unstructured":"Glasheen WP, Cordier T, Gumpina R, Haugh G, Davis J, Renda A. Charlson Comorbidity Index: ICD-9 Update and ICD-10 Translation. Am Health Drug Benefits. 2019;12:188\u201397.","journal-title":"Am Health Drug Benefits"},{"key":"4501_CR32","unstructured":"National Health Insurance Administration M. Taiwan Ministry of Health and Welfare, National Health Insurance Administration \u2013 Latest Drug Reimbursement Guidelines \u2013 Section VI: Respiratory Medications. (Updated August 28, 2024). 2025."},{"key":"4501_CR33","doi-asserted-by":"publisher","first-page":"e0305429","DOI":"10.1371\/journal.pone.0305429","volume":"19","author":"K Sugino","year":"2024","unstructured":"Sugino K, Ono H, Saito M, Ando M, Tsuboi E. Tolerability and efficacy of switching anti-fibrotic treatment from nintedanib to pirfenidone for idiopathic pulmonary fibrosis. PLoS ONE. 2024;19:e0305429. https:\/\/doi.org\/10.1371\/journal.pone.0305429.","journal-title":"PLoS ONE"},{"key":"4501_CR34","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12931-024-02705-5","volume":"25","author":"M Sridhar","year":"2024","unstructured":"Sridhar M, Bodduluri S, O\u2019Hare L, Blumhoff S, Acosta Lara MDP, de Andrade JA, et al. Association of musculoskeletal involvement with lung function and mortality in patients with idiopathic pulmonary fibrosis. Respir Res. 2024;25:81. https:\/\/doi.org\/10.1186\/s12931-024-02705-5.","journal-title":"Respir Res"},{"key":"4501_CR35","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1159\/000518855","volume":"101","author":"S Jouneau","year":"2022","unstructured":"Jouneau S, Crestani B, Thibault R, Lederlin M, Vernhet L, Yang M, et al. Post hoc analysis of clinical outcomes in placebo- and pirfenidone-treated patients with IPF stratified by BMI and weight loss. Respiration. 2022;101:142\u201354. https:\/\/doi.org\/10.1159\/000518855.","journal-title":"Respiration"},{"key":"4501_CR36","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s12931-020-01528-4","volume":"21","author":"S Jouneau","year":"2020","unstructured":"Jouneau S, Crestani B, Thibault R, Lederlin M, Vernhet L, Valenzuela C, et al. Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis. Respir Res. 2020;21:312. https:\/\/doi.org\/10.1186\/s12931-020-01528-4.","journal-title":"Respir Res"},{"key":"4501_CR37","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s12325-020-01523-7","volume":"38","author":"S Noor","year":"2021","unstructured":"Noor S, Nawaz S, Chaudhuri N. Real-world study analysing progression and survival of patients with idiopathic pulmonary fibrosis with preserved lung function on antifibrotic treatment. Adv Ther. 2021;38:268\u201377. https:\/\/doi.org\/10.1007\/s12325-020-01523-7.","journal-title":"Adv Ther"},{"key":"4501_CR38","doi-asserted-by":"publisher","unstructured":"Antoniou K, Markopoulou K, Tzouvelekis A, Trachalaki A, Vasarmidi E, Organtzis J, et al. Efficacy and safety of nintedanib in a Greek multicentre idiopathic pulmonary fibrosis registry: a retrospective, observational, cohort study. ERJ Open Res. 2020;6. https:\/\/doi.org\/10.1183\/23120541.00172-2019.","DOI":"10.1183\/23120541.00172-2019"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-026-04501-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04501-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04501-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T13:02:31Z","timestamp":1791810151000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12890-026-04501-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4501"],"URL":"https:\/\/doi.org\/10.1186\/s12890-026-04501-x","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"assertion":[{"value":"8 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of Taichung Veterans General Hospital (IRB No. CE18325B; approved December 18, 2018).Written informed consent was obtained from all participants involved in this study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"458"}}